News >

Expert Discusses Expansion of T-VEC in Melanoma

Caroline Seymour
Published: Wednesday, Dec 12, 2018

Robert Andtbacka, MD

Robert Andtbacka, MD
Although the oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) is approved for patients with advanced-stage unresectable melanoma, Robert Andtbacka, MD, explained that it holds promise beyond its current indication as a potential neoadjuvant therapy and in combination with PD-1 inhibitors.

, Andtbacka, an associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discussed the current use of T-VEC in melanoma and future directions with this type of treatment.

OncLive: What is the evolution of T-VEC since its 2015 FDA approval?

Andtbacka: T-VEC was approved as monotherapy for patients in the United States with metastatic unresectable melanoma—stage III/IV melanoma. It's been used in that setting, but mostly in patients who have earlier disease. These are patients with unresectable stage III disease and some stage IV N1a disease. I don't think T-VEC is being used much in patients with lung and liver metastases. When T-VEC was approved, there were institutions around the country who were using it as monotherapy, but also in combination with PD-1 inhibitors and other therapies, as well.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication